A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT06703177
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-1826 — DRUG
    SHR-1826
  • SHR-4642 — DRUG
    SHR-4642
  • SHR-9839 — DRUG
    SHR-9839
  • SHR-8068 — DRUG
    SHR-8068
  • Bevacizumab Injection — DRUG
    Bevacizumab Injection
  • Fluorouracil Injection — DRUG
    Fluorouracil Injection
  • Calcium Folinate Injection — DRUG
    Calcium Folinate Injection
  • Adebrelimab Injection — DRUG
    Adebrelimab Injection
  • Capecitabine tablets — DRUG
    Capecitabine tablets, oral.

Study Details

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

Key Dates

First listed
Nov 25, 2024
Start date
Feb 18, 2025
Status verified
Nov 2025
Primary completion
Jan 1, 2026
Completion
Jul 1, 2027

Study Design

Enrollment
876 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single group

Primary Outcome Measure

RP2D (Phase 1) [ Time Frame: Screening up to study completion, an average of 1 year. ]

Central Contacts

Related Studies